217 related articles for article (PubMed ID: 9876203)
1. Pharmacokinetics of cefodizime in patients with various degrees of renal failure.
Loffreda A; Lampa E; Lucarelli C; Amorena M; Contaldi C; Calderaro V; Rossi F
Chemotherapy; 1999; 45(1):1-7. PubMed ID: 9876203
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of cefodizime following single doses of 0.5, 1.0, 2.0, and 3.0 grams administered intravenously to healthy volunteers.
Lenfant B; Namour F; Logeais C; Coussediere D; Rivault O; Bryskier A; Surjus A
Antimicrob Agents Chemother; 1995 Sep; 39(9):2037-41. PubMed ID: 8540712
[TBL] [Abstract][Full Text] [Related]
3. Dose linearity and other pharmacokinetics of cefodizime after single-dose intravenous administration.
Dagrosa EE; Hajdú P; Malerczyk V; de Looze S; Seeger K; Grötsch H
Clin Ther; 1987; 10(1):18-31. PubMed ID: 3450392
[TBL] [Abstract][Full Text] [Related]
4. Single-dose pharmacokinetics of cefodizime in critically ill elderly patients.
Meyer B; Traunmueller F; Bojic A; Locker G; Schmid R; Winkler S; Thalhammer F
Int J Antimicrob Agents; 2006 Apr; 27(4):335-8. PubMed ID: 16563704
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of cefodizime in normal individuals and in patients with renal failure.
el Guinaidy MA; Nawishy S; Abd el Bary M; Sabbour MS
Chemotherapy; 1991; 37(2):77-85. PubMed ID: 2032473
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of cefodizime administered intravenously as a single-dose (1.0 and 2.0 g) to healthy adult volunteers.
Bryskier A; Procyk T; Tremblay D; Lenfant B; Fourtillan JB
J Antimicrob Chemother; 1990 Nov; 26 Suppl C():65-70. PubMed ID: 2074253
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of cefodizime in elderly patients with moderate or severe renal impairment.
Veyssier P; Devillers A; Domart Y; Fourtillan JB; Bryskier A; Procyk T
J Antimicrob Chemother; 1990 Nov; 26 Suppl C():77-81. PubMed ID: 2074255
[TBL] [Abstract][Full Text] [Related]
8. Cefodizime in skin suction blister fluid and serum following a single intravenous or intramuscular dose in adult patients.
Mazzei T; Novelli A; Esposito S; Fallani S; Noviello S; Cassetta MI; Conti S; Periti P
J Chemother; 2000 Aug; 12(4):306-13. PubMed ID: 10949980
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of cefodizime: a review of the data on file.
Barré J
J Antimicrob Chemother; 1990 Nov; 26 Suppl C():95-101. PubMed ID: 2074258
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of cefodizime in volunteers with normal or impaired renal function.
Conte JE
J Clin Pharmacol; 1994 Nov; 34(11):1066-70. PubMed ID: 7876397
[TBL] [Abstract][Full Text] [Related]
11. The pharmacokinetics of cefodizime in children.
Boccazzi A; Fusi G; Mezzopane AM; Maretti M; Careddu P
J Antimicrob Chemother; 1990 Nov; 26 Suppl C():83-7. PubMed ID: 2074256
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of cefodizime in the elderly following single and repeated intravenous administration of 1 g.
Nilsen OG; Rennemo F; Rennemo R; Lenfant B
J Antimicrob Chemother; 1990 Nov; 26 Suppl C():71-5. PubMed ID: 2074254
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of cefodizime during continuous ambulatory peritoneal dialysis.
Mendes P; Lameire N; Rosenkranz B; Malerczyk V; Damm D
J Antimicrob Chemother; 1990 Nov; 26 Suppl C():89-93. PubMed ID: 2074257
[TBL] [Abstract][Full Text] [Related]
14. Cefodizime penetration into skin suction blister fluid following a single intravenous dose.
Schäfer-Korting M; Korting HC; Maass L; Klesel N; Grigoleit HG; Mutschler E
Eur J Clin Pharmacol; 1986; 30(3):295-8. PubMed ID: 3732363
[TBL] [Abstract][Full Text] [Related]
15. Cefodizime in serum and skin blister fluid after single intravenous and intramuscular doses in healthy volunteers.
Korting HC; Schäfer-Korting M; Maass L; Klesel N; Mutschler E
Antimicrob Agents Chemother; 1987 Nov; 31(11):1822-5. PubMed ID: 3435129
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of cefodizime in patients with liver cirrhosis and ascites.
el Touny M; el Guinaidy M; Abdel Bary M; Osman L; Sabbour MS
Chemotherapy; 1992; 38(4):201-5. PubMed ID: 1473357
[TBL] [Abstract][Full Text] [Related]
17. The effects of renal impairment on the pharmacokinetics and safety of fosfluconazole and fluconazole following a single intravenous bolus injection of fosfluconazole.
Sobue S; Tan K; Layton G; Leclerc V; Weil A
Br J Clin Pharmacol; 2004 Jun; 57(6):773-84. PubMed ID: 15151523
[TBL] [Abstract][Full Text] [Related]
18. Dosing time and sex-related differences in the pharmacokinetics of cefodizime and in the circadian cortisol rhythm.
Jonkman JH; Reinberg A; Oosterhuis B; de Noord OE; Kerkhof FA; Motohashi Y; Levi F; Dammacco F; Carandente F
Chronobiologia; 1988; 15(1-2):89-102. PubMed ID: 3416675
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic study of cefodizime and ceftriaxone in sera and bones of patients undergoing hip arthroplasty.
Scaglione F; De Martini G; Peretto L; Ghezzi R; Baratelli M; Arcidiacono MM; Fraschini F
Antimicrob Agents Chemother; 1997 Oct; 41(10):2292-4. PubMed ID: 9333066
[TBL] [Abstract][Full Text] [Related]
20. Effect of renal impairment on the pharmacokinetics of intravenous zanamivir.
Cass LM; Efthymiopoulos C; Marsh J; Bye A
Clin Pharmacokinet; 1999; 36 Suppl 1():13-9. PubMed ID: 10429836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
